SGLT2抑制剂在80岁以上CKD患者中的肾心获益与风险
Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
一项基于电子健康记录的观察性分析纳入10,076名80岁及以上慢性肾脏病(CKD)成人,结果显示两年随访期间启动SGLT2抑制剂治疗与全因死亡率降低18%及主要不良肾脏事件降低22%相关;严重不良心血管事件整体无显著影响,但心肌梗死、急性心力衰竭及急性肾损伤风险升高。
基于1万余名80岁以上CKD患者的真实世界数据,提示SGLT2抑制剂在该人群中的肾心获益与特定风险。
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
In their analysis of electronic health records data on 10,076 adults aged 80 years or older with CKD, investigators found that over a two-year follow-up, initiating SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality and a 22% reduction in major adverse kidney events. There was no significant effect on major adverse cardiovascular events overall, but SGLT2 inhibitors were associated with higher risks of specific cardiac events like heart attacks and acute heart failure, as well as acute kidney injury.
"Very elderly individuals are historically underrepresented in or systematically excluded from large-scale randomized controlled trials due to multimorbidity and frailty. By leveraging real-world data, our research addresses a crucial blind spot in current medical literature," said corresponding author Bernhard M. W. Schmidt, M.D., S.M., from the Department of Nephrology and Hypertension at Hannover Medical School in Germany.
"Even the oldest and most vulnerable CKD patients can derive substantial benefits from SGLT2 inhibitor treatment, but these medications may not be without risk in this demographic. These patients require a careful, individualized risk-benefit assessment and close clinical monitoring."
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease (2026, October 24) retrieved 24 October 2026 from https://medicalxpress.com/news/2026-10-advanced-age-limit-benefits-sodium.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com